MedTrace Logo

A Study Of Tasocitinib In Dry Eye Subjects

NCT01226680 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-11-29

No results posted yet for this study

Summary

This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease. Both subjective and objective clinical endpoints will be measured for a duration of 12-week treatment.

Conditions

  • Keratoconjunctivitis Sicca

Interventions

DRUG

Tasocitinib

0.005% QD for 12 weeks

DRUG

Tasocitinib

0.003% QD for 12 weeks

DRUG

vehicle for Tasocitinib

vehicle QD for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-01
Primary Completion
2012-10-19
Completion
2012-10-19

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226680 on ClinicalTrials.gov